Peripheral Intervention

  • Data from Japan support <br/>DES in real-world lesions

    product

    Data from Japan support
    DES in real-world lesions

    Two-year results of the Zilver® PTX® post-market surveillance study in Japan were presented at CIRSE and indicate a continued low rate of revascularization in patients with complex lesions and comorbidities. There were no exclusion criteria.

    Read More
  • First-year fellows<br/> in the Big Apple

    feature

    First-year fellows
    in the Big Apple

    Two fellows share their thoughts on starting the first year of their vascular surgery fellowship programs at NewYork-Presbyterian/Weill Cornell Medical Center and NewYork-Presbyterian/Columbia University Medical Center.

    Read More
  • A rich history<br/>of partnership<br/>with physicians

    feature

    A rich history
    of partnership
    with physicians

    It's been more than a half-century since Bill Cook began working with Charles Dotter. That collaboration shaped today's Cook Medical when it brings new products to market.

    Read More
  • Cross lesions<br/> with just one set

    technology

    Cross lesions
    with just one set

    TriForce® Peripheral Crossing Set was designed to cross vascular lesions using a tungsten-loaded tip to aid pushability. This animation shows how it works.

    Read More
Experience the new era in SFA treatment with drug elution
Plus

Experience the new era in SFA treatment with drug elution

Achieve superior outcomes with the only SFA stent that has a proven drug effect.

Learn MoreLearn More
Download the Peripheral Intervention catalog
Plus

Download the Peripheral Intervention catalog

This 2014 catalog includes more than 2,000 stock products that are approved for sale in the U.S.

Learn MoreLearn More

Competitive spirit in full force for EndoWars

January 18th, 2016
  • Tags:
EndoWar winners, from left to right: Drs. Mohammed Al-Natour, Mohammad Abbasi, Sandeep Krishnan, Adam Tanious

EndoWars is an educational opportunity for fellows and residents to practice endovascular procedures and refine their skills. A group of fellows and residents recently competed against each other to see who could complete a successful procedure in the fastest time.

Read More »

7 key points from VIVA 15

January 15th, 2016
  • Tags:

Vascular Interventional Advances (VIVA) is an annual meeting dedicated to global education in vascular medicine and intervention. VIVA 15 was an exciting meeting with late-breaking trial results and talks by leading physicians. Below are some of the topics that were discussed by physicians on the VIVA podiums: 1. Japan Post-Market Surveillance (PMS) study results provide confidence. Zilver PTX added to its strong data…

Read More »

No exclusion criteria: Japan PMS study confirms 2-year benefits of Zilver® PTX®

December 11th, 2015
  • Tags:
ZPTX-306x196

Recently released data on the Japan post-market surveillance (PMS) study showed two-year patency rates of 72.3%1, while the Zilver PTX randomized controlled trial (RCT) patency results were 76.3%2 at the same mark. In addition, the Japan PMS showed 85.0%3 two-year freedom from target lesion revascularization (TLR). Two other major Zilver PTX trials showed similar numbers…

Read More »

Showing 1 - 4 of 108 results.

Upcoming Events

  • January 20, 2016 - January 23, 2016
    SAVS 2016 - Annual Meeting Southern Association for Vascular Surgery
    Cancun, Mexico
  • February 6, 2016 - February 10, 2016
    ISET 2016 - International Symposium on Endovascular Therapy
    Hollywood, Florida
  • February 20, 2016 - February 23, 2016
    CRT 2016 - Cardiovascular Research Technologies
    Washington D. C.
  • February 24, 2016 - February 26, 2016
    AVF 2016 - American Venous Forum
    Orlando, Florida
  • April 2, 2016 - April 7, 2016
    SIR 2016 - Society of Interventional Radiology
    Vancouver, British Columbia

Social Media

linkedin youtube
Give Us Feedback